Q-omics provides the consensus-scored GPD1L profile across patient tissues and cancer cell-line models. GPD1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPD1L is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, GPD1L protein abundance shows 31,247 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where GPD1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPD1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPD1L survival associations across molecular data types. GPD1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPD1L RNA expression–survival associations across cancer types. High GPD1L expression shows unfavorable associations in LIHC, but favorable associations in KIRC, KIRP, LUAD, UVM and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPD1L RNA expression.
This table summarizes GPD1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPD1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPD1L shows lower tumor expression in HNSC, KIRC, COAD, THCA, LUSC and LUAD. The HNSC box plot shows higher GPD1L RNA expression in normal versus tumor tissue (log2 FC = −2.137, t-test p < 0.001).
This table shows molecular features associated with GPD1L in patient tissues and cancer cell lines. In patient samples, GPD1L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GPD1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
